Tagged with Global

Global AstraZeneca’s CEO Pascal Soriot warns that the new US legislation controlling drug prices would reduce innovators’ capacity to recover drug development investments and therefore discourage innovation, especially for drugs with smaller patient pools. In a Reuters interview last week Soriot said the law recently passed in the United States that would…

Global The news is filled with stories of woe in the airline industry. Bags being lost, flights being cancelled, planes being stranded on the tarmac, hours – days even – spent stranded at airports waiting for services promised but never delivered. Both the airline and health sectors have been hit by…

Global After the prolonged underperformance of its generics division, Sandoz, Novartis has announced a spin off that will allow the company to focus on its core business and which is part of a broader paring down strategy. For Novartis, the separation of Sandoz would further support our strategy of building a…

Global Merck has agreed to front USD 150 million for Orna Therapeutics’ new investigational class of engineered circular RNA (oRNA) therapies in a collaboration agreement that will also provide the biotech series B financing. This broad strategic collaboration brings together Merck’s significant expertise … with Orna’s compelling circular RNA technology to…

Global Sarah Pope Miksinski, executive director/CMS regulatory affairs, and Gregory Rullo, senior director regulatory affairs, at AstraZeneca discuss the need for common ground among regulators and industry when it comes to patient centricity and for strategic leadership to address differing regulatory control-strategy requirements. In today’s increasingly complex and intricate pharmaceutical landscape,…

Global While COVID-19 demonstrated the biopharma industry’s capacity for innovation and its ability to scale up manufacturing, it also exposed the challenges of ensuring equitable distribution of vaccines. In an effort to work towards solving these issues and being better prepared to respond to future pandemics, the industry has created the…

Global DIA 2022 convened with an opening plenary that explored the question What is the Future of Healthcare? from four connected perspectives—Inclusive, Global, Individual, Digital.   Barbara Lopez Kunz, Global Chief Executive, DIA “We’re here this week because we imagine a world where powerful health interventions and tools are rapidly discovered,…

Global After almost four years leading Sanofi’s second largest market, China, Pius S. Hornstein moves into a global role to focus on the company’s digital transformation. “In the last 8 years, I have been witnessing the incredible opportunities that digital could unlock …” he said in a LinkedIn post announcing the…

Global Pharma companies no longer view digital as a “nice to have” add on, but as an integral part of their business, yet there are still quite a few hurdles to overcome. Insights from pharma industry digital transformation leaders. Industry is on a dedicated and focused journey to leverage data and…

Global Since monkeypox was declared a global emergency by the World Health Organization (WHO) and industrialized countries began stockpiling vaccines, Bavarian Nordic’s shares have more than tripled while Siga Technologies has seen the value of its stock double.   … we are pleased to assist more countries with supply of vaccines…

Global Merck Group’s Vice President Global Market Access & Pricing Strategic Planning, Marco Rauland, takes a look at recent advancements in Machine Learning and Artificial Intelligence and how these technologies can offer a sophisticated and flexible approach not only to predicting drug pricing, but also to estimating market access with different…

Global Swiss pharma giant, Roche, has announced a change in leadership that will see Severin Schwan replaced by diagnostics division head, Thomas Schinecker, after a 14-year stint as CEO. Schinecker, who became a contender for the role by leading the company’s efforts in developing a COVID-19 test kit, growing sales by…